Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.
NCT07668219 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2026-06-25
Summary
* Rationale: Glucose control in patients with kidney disease is challenging, as traditional metrics can be unreliable and there is a high risk of hypoglycemia (low blood sugar). Although RT-CGM has shown benefits in other groups, its efficacy in patients with advanced kidney damage needs to be validated to improve their quality of life and prevent disease progression.
* Main objective: To determine whether the use of RT-CGM is more effective than usual care (capillary blood glucose monitoring with a glucometer) in maintaining patients within an optimal glucose range (70-180 mg/dL) over a three-month period.
* Study population: We plan to include 30 patients over 18 years of age with type 2 diabetes and chronic kidney disease (with a glomerular filtration rate less than 60 ml/min), who use insulin and are not on renal replacement therapy such as dialysis.
* Methodology: The study is a randomized clinical trial consisting of two phases:
1. Selection period (15 days): Blinded monitoring is performed to obtain baseline data.
2. Treatment period (90 days): Patients are divided into two groups: the intervention group, which will use the CGM-RT with alarms configured for high and low levels, and the control group, which will continue with traditional fingerstick monitoring.
* Metrics to be evaluated: In addition to time in range, researchers will analyze episodes of hypoglycemia and hyperglycemia, glycemic variability, glycated hemoglobin (HbA1c) levels, and device accuracy.
* Ethical and logistical considerations: The study complies with international and national regulations, guaranteeing the confidentiality and autonomy of the participants. The project has a 24-month timeline and a detailed budget to cover medical personnel, monitoring sensors (Sinocare i3), and laboratory tests.
Conditions
- Type 2 Diabetes
- Kidney Disease
- CGM
- Time in Range
Interventions
- DEVICE
-
Real time continuos glucose monitoring
Intervention group (users of real-time continuous glucose monitoring). Participants in the intervention group will be instructed on the use of real-time continuous glucose monitoring. This training will be provided by nursing staff and will include instruction on device use, alarm management, and recommendations for responding to hypoglycemic episodes reported by the device. Alarms will be configured as follows: High Glucose Alert ≥240 mg/dL and Low Glucose Alert ≤70 mg/dL. Data uploaded to the platform by the device will be reviewed monthly by a physician trained in diabetes management, who will make appropriate adjustments to therapy if participants experience hypoglycemic episodes (\<54 mg/dL and \<70 mg/dL) or recurrent hyperglycemic episodes (\>180 mg/dL), according to basal and prandial insulin titration recommendations. This group will be instructed to confirm readings below 70 mg/dL and above 240 mg/dL with capillary blood glucose monitoring to evaluate the device's accuracy withi
- DEVICE
-
self blood glucose monitoring
Control group: Continuous glucose monitoring will be installed, blinded to measure baseline glycemic control metrics and at the end of the study. Patients assigned to the control group will receive routine nursing education on glucometer use, frequency of capillary blood glucose monitoring, and recommendations for managing hypoglycemic episodes. Capillary glucose data will be reviewed monthly by a physician trained in diabetes management, who will make appropriate adjustments to therapy if subjects experience hypoglycemic events (\<54 mg/dL and \<70 mg/dL) or recurrent hyperglycemic events (\>180 mg/dL), according to basal and prandial insulin titration recommendations.
Sponsors & Collaborators
-
Hospital Universitario San Ignacio
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-11-30
- Primary Completion
- 2027-02-01
- Completion
- 2027-05-30
Countries
- Colombia
More Related Trials
-
Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial
NCT05509881 ·Status: RECRUITING ·Phase: NA
-
Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin
NCT01175408 ·Status: COMPLETED ·Phase: NA
-
Community Glucose Monitoring Project
NCT05351190 ·Status: UNKNOWN ·Phase: NA
-
Continuous Glucose Monitoring for Post-kidney Transplantation in Pre-existing Type 2 Diabetes
NCT07271433 ·Status: COMPLETED
-
Continuous Glucose Monitoring (CGM) After Kidney Transplantation
NCT06675903 ·Status: RECRUITING
-
Continuous Glucose Monitoring in People With Diabetes on Dialysis
NCT06657508 ·Status: ACTIVE_NOT_RECRUITING
-
The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA
NCT01787903 ·Status: COMPLETED ·Phase: NA
-
Examining The Role of CGM in T2DM
NCT01614262 ·Status: COMPLETED ·Phase: NA
-
Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.
NCT06607224 ·Status: COMPLETED ·Phase: NA
-
Use of CGM in Kidney Transplant Recipients
NCT04783441 ·Status: RECRUITING ·Phase: NA
-
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
NCT00529815 ·Status: UNKNOWN ·Phase: PHASE4
-
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
NCT02009514 ·Status: COMPLETED ·Phase: PHASE4
-
The Management of Glucose Control and Hypoglycemic Prevention Using Continuous Glucose Monitoring System in Patients With Type 1 Diabetes
NCT04684030 ·Status: UNKNOWN ·Phase: NA
-
RT-CGM in Young Adults at Risk of DKA
NCT04039763 ·Status: RECRUITING ·Phase: NA
-
Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes
NCT03207893 ·Status: COMPLETED ·Phase: NA
-
Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control
NCT07006480 ·Status: RECRUITING ·Phase: NA
-
Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes
NCT02282397 ·Status: COMPLETED ·Phase: NA
-
Continuous Glucose Monitoring in Peri-operative Period in Kidney Transplant Recipients
NCT06012799 ·Status: UNKNOWN
-
Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control
NCT06591286 ·Status: RECRUITING ·Phase: NA
-
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
NCT05947916 ·Status: RECRUITING ·Phase: NA
-
Effectiveness of Glunovo Real-Time Continuous Glucose Monitoring in Adults With Type 2 Diabetes
NCT07089979 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
NCT04436822 ·Status: COMPLETED ·Phase: NA
-
A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes
NCT02258373 ·Status: COMPLETED ·Phase: NA
-
Real-world Effect of Switching From Intermittently-scanned to Real-time Continuous Glucose Monitoring (Switch CGM Retro)
NCT06962735 ·Status: COMPLETED
-
The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.
NCT06111508 ·Status: COMPLETED ·Phase: NA